These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 14529558)

  • 1. The effects of antihypertensive therapy on haemostatic parameters.
    Ganotakis ES; Papadakis JA; Vrentzos GE; Mikhailidis DP
    Curr Pharm Des; 2003; 9(29):2445-64. PubMed ID: 14529558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise.
    Braschi A
    Am J Cardiovasc Drugs; 2019 Apr; 19(2):133-171. PubMed ID: 30714087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant?
    Fogari R; Zoppi A
    Am J Cardiovasc Drugs; 2005; 5(4):211-23. PubMed ID: 15984904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does hypertension confer a hypercoagulable state?
    Lip GY; Li-Saw-Hee FL
    J Hypertens; 1998 Jul; 16(7):913-6. PubMed ID: 9794730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of pleiotropic effects of angiotensin-converting enzyme inhibitors].
    Zagidullin NSh; Valeeva KF; Gassanov F; Zagidullin ShZ
    Kardiologiia; 2010; 50(11):55-60. PubMed ID: 21526566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prothrombotic state in hypertension and the effects of antihypertensive treatment.
    Nadar S; Lip GY
    Curr Pharm Des; 2003; 9(21):1715-32. PubMed ID: 12871204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with ramipril favourably modifies the haemostatic response to acute submaximal exercise in hypertensives.
    Galea V; Triantafyllidi H; Theodoridis T; Koutroumbi M; Christopoulou-Cokkinou V; Kremastinos D; Anastasiou-Nana M; Lekakis J
    J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):322-9. PubMed ID: 23178512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension.
    Remková A; Kratochvíl'ová H; Durina J
    J Hum Hypertens; 2008 May; 22(5):338-45. PubMed ID: 18305548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aliskiren, a renin inhibitor, on biomarkers of platelet activity, coagulation and fibrinolysis in subjects with multiple risk factors for vascular disease.
    Serebruany VL; Malinin A; Barsness G; Vahabi J; Atar D
    J Hum Hypertens; 2008 May; 22(5):303-10. PubMed ID: 18273042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.